GBL Backs CVC Offer to Buy Italy’s Recordati for $12 Billion Global Biologicals Limited (GBL) has thrown its weight behind CVC Capital Partners' proposed acquisition of Recordati Pharmaceuticals.
The move could shake up the Italian pharmaceutical market and have far reaching implications for the global generics industry, particularly given GBL's ambitions to expand its presence in Europe.
Background and Context GBL has been quietly building its operations over the past few years through a series of strategic acquisitions that have helped establish it as a major force in the generics market.